# KMTS earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/KMTS) · [Earnings tab](https://www.lopjlb.com/stock/KMTS?tab=earnings) Updated: 2026-09-16T09:28:28 Quarters analyzed: 5 ## Cross-quarter narrative Across five quarters, Kestra’s earnings calls trace a trajectory of accelerating top‑line growth and steady margin improvement while wrestling with persistent market‑penetration and payer‑coverage challenges. Revenue growth rose from 52 % in Q1 2026 to a peak of 66 % in Q4 2026 before moderating to 60 % in Q1 2027, prompting successive FY guidance lifts. Gross margins climbed from an expanding trajectory toward 70 %+ to 56.5 % by Q1 2027, reflecting rental‑model economics and cost‑per‑fit reductions. The company broadened its sales footprint, reaching 130 territories and deepening in‑network payer mixes, yet repeatedly flagged the long tail of ~3,000 regional payers and the under‑utilization of WCD therapy (≈14 % of eligible patients). Cash burn remained high, spiking to $28 M in Q3 2026 and persisting into 2027, underscoring liquidity pressure. Milestone activity shifted from early study completions and payer additions to algorithm upgrades, a BioBeat partnership, and a new AI‑automation program, indicating a move toward technology‑driven efficiency. Competitive and regulatory risks were consistently noted, while new R&D and AI initiatives entered the pipeline, marking the latest strategic focus. ## Latest CallCard · Q1 Kestra posted 60% revenue growth to $31M, expanded gross margin to 56.5%, raised FY27 revenue guidance to $141M and highlighted AI/automation, R&D and payer‑contract initiatives while noting ongoing execution risks. **Guidance:** raised — Revenue guidance lifted to $141M from $137M, reflecting confidence in volume and mix drivers. **Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.3 Management expressed excitement about strong financial performance, margin expansion and confidence in achieving mid‑70% gross margins. ### Demand visibility Improving demand visibility through expanding in‑network payer mix and new contracts In‑network mix now in the low 80s%, addition to the VA federal supply schedule, a national payer now covering non‑ischemic patients, and ongoing work with ~3,000 regional payers. ### Margins / costs Gross margin expanding, targeting mid‑70% Q1 gross margin 56.5% (11 quarters of sequential expansion); improvements driven by higher revenue per fit from in‑network mix and cost‑per‑fit reductions. ### Capital allocation Capital allocated to commercial expansion, AI/automation, R&D, and balance‑sheet strengthening Secured a $200M term loan, R&D spend up ~70% in Q1 to accelerate late‑stage projects, AI initiatives tied to rep productivity, and continued field‑team hiring. ### Milestones - **AI automation initiative** [new]: AI‑powered patient support agents, automated outreach, revenue‑cycle automation and commercial demand acceleration. - **Biobeat integration** [on_track]: Integrating non‑invasive blood pressure monitoring into the ASSURE platform. - **Late‑stage R&D project** [on_track]: First‑in‑category capability for ASSURE system, details to be shared next quarter. - **VA supply schedule addition** [delivered]: Added to the U.S. Department of Veterans Affairs federal supply schedule. - **National payer coverage expansion** [delivered]: Significant national payer now covers non‑ischemic patients, a first for that segment. - **Territory splitting strategy** [on_track]: Splitting high‑volume platinum territories to boost rep productivity and market penetration. - **$200M term loan facility** [delivered]: Non‑dilutive financing strengthens balance sheet and provides flexibility for growth. - **R&D acceleration** [new]: R&D spend increased 70% Q1 to finalize multiyear program, expected to normalize H2. ### Fears / risks - **Payer coverage uncertainty**: Remaining ~3,000 regional/local payers not yet in‑network could limit revenue per fit growth. - **AI impact timeline**: Operating expense benefits from AI automation are expected to materialize in FY28‑29, not immediately. - **R&D cost volatility**: Q1 R&D spend surged 70%, potentially pressuring operating expenses before returning to historical levels. - **Cash burn**: Higher Q1 cash burn due to bonus payouts and supplier timing; reliance on term loan for liquidity. - **Competitive pressure**: WCD market remains under‑penetrated; incumbent competitors could affect share gains. - **Regulatory risk**: Medical device approvals and reimbursement policy changes could affect product rollout. - **Supply chain cost risk**: Cost‑per‑fit reductions depend on supplier volume discounts, which could fluctuate. - **Market adoption risk**: Patient adoption hinges on clinical evidence and payer reimbursement decisions. ### Key quotes > “We're excited to discuss the strong financial performance we had in the first quarter and the continued progress we are making on our key operational objectives.” — Brian Webster > “Revenue advanced sequentially off a strong fourth quarter and grew 60% year-over-year to $31 million.” > “What gave you the confidence to raise by more than the beat this quarter?” > “We're obviously excited by the start to the year. We're certainly bullish on our story.” — Brian Webster ## Quarter one-liners - **2027 Q1:** Kestra posted 60% revenue growth to $31M, expanded gross margin to 56.5%, raised FY27 revenue guidance to $141M and highlighted AI/automation, R&D and payer‑contract initiatives while noting ongoing execution risks. - **2026 Q4:** Kestra reported 66% Q4 revenue growth, expanding gross margins to 54.8% and sales territories to 130, while highlighting ongoing commercial expansion, product upgrades and a still‑under‑penetrated WCD market. - **2026 Q3:** KestrA Medical posted 63% revenue growth and 52.6% gross margin in Q3, announced an FDA‑approved algorithm update, a BioBeat partnership, expanded payer contracts and a $9M capex spend while targeting 130 sales territories by fiscal year‑end. - **2026 Q2:** KestrA Medical posted 53% revenue growth, lifted gross margin above 50% for the first time and raised FY2026 revenue guidance, while highlighting strong clinical evidence and expanding sales and payer coverage. - **2026 Q1:** Kestra posted 52% revenue growth, expanding gross margins toward 70%+, raised FY26 revenue guidance to $88M, and highlighted a completed ASSURE post‑approval study and upcoming AHA presentation while emphasizing compliance and steady commercial investment. ## Theme arcs - **Revenue growth** (improving): Quarterly growth rates rose from 52% to 66% before a modest dip to 60% - **Gross margin expansion** (improving): Margins moved from just above 50% to 56.5%, targeting mid‑70% - **Payer coverage expansion** (improving): In‑network mix grew, new VA and national contracts added - **Market adoption/underutilization** (stable): WCD therapy remains at ~14% of eligible patients across calls - **Cash burn and liquidity** (deteriorating): Quarterly cash burn peaked at $28M and liquidity concerns persisted - **Commercial expansion (sales territories)** (improving): Territories grew to 130, with ongoing splitting strategy - **Competitive risk** (stable): Consistent mention of need to maintain differentiation - **Regulatory/algorithm updates** (new): FDA‑approved algorithm update and enhanced ASSURE detection released - **AI/automation and R&D** (new): AI automation initiative and late‑stage R&D project introduced in Q1 2027 - **Capital investment** (improving): Capex spend rose to $9M and continued allocation to fleet and commercial assets ## Guidance path 2026 Q1:raised → 2026 Q2:raised → 2026 Q3:vague → 2026 Q4:vague → 2027 Q1:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/KMTS`